Cascadian Therapeutics (CASC) Proposes Reverse Stock Split
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Cascadian Therapeutics Announces Proposal for Reverse Stock Split
October 4, 2016 4:11 PM EDTSEATTLE, Oct. 04, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics (NASDAQ: CASC), a clinical-stage biopharmaceutical company, today announced that its board of directors has approved a plan for a reverse split of the Companys common stock to increase its share price and reduce the number of authorized and outstanding shares.
The board and management have worked diligently on several facets of the Company this year to position it for the future, including bringing in new management, and solidifying our product development and regulatory strategies. With this action, we are helping ensure that the... More